ストックスクリーナーアプリを入手
10.50
1.06%
0.11
前日終値:
$10.39
開ける：
$10.78
24時間の取引高:
19,270
Relative Volume:
1.22
時価総額：
$7.10M
収益：
-
当期純損益:
$-18.82M
株価収益率:
-0.3367
EPS:
-31.1883
ネットキャッシュフロー:
$-14.79M
1週間 パフォーマンス:
-4.46%
1か月 パフォーマンス:
+3.45%
6か月 パフォーマンス:
-11.39%
1年 パフォーマンス:
-69.07%
1日の値動き範囲:
$10.20
$11.15
1週間の範囲:
$10.15
$12.49
52週間の値動き範囲:
$8.67
$39.20
Envveno Medical Corp Stock (NVNO) Company Profile
Compare NVNO vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corp
|
10.40 | 7.15M | 0 | -18.82M | -14.79M | -31.19 |
ABT
Abbott Laboratories
|
116.35 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
331.50 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
93.08 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
50.77 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.90 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Envveno Medical Corp (NVNO) 最新ニュース
Perceptive Advisors (NVNO) reports 3.5% beneficial stake via 24,605 warrants - Stock Titan
NVNO Q2 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 8.54%Estimate Uncertainty - Vinanet
NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development CostsEPS Consistency Score - Vinanet
enVVeno study shows $32,000 savings per patient for venous valve therapy - scanx.trade
enVVeno Medical (NVNO) Highlights Cost-Effectiveness of VenoValve Amid Challenging Valuation Metrics - GuruFocus
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments - ACCESS Newswire
enVVeno Study Projects About 2.2 Fewer Venous Ulcers Per Patient - Stock Titan
enVVeno cites Journal of Vascular Surgery study showing venous valve therapy saves more than $32,000 per patient over five years - Bitget
EnVVeno Moves Toward U.S. Pivotal Trial - Orange County Business Journal
enVVeno Medical receives FDA approval for pivotal trial By Investing.com - Investing.com Nigeria
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve - Weatherford Democrat
enVVeno Medical Corp reports results for the quarter ended June 30Earnings Summary - TradingView
enVVeno Medical Corp Q2 2026: Revenue —, Net loss $3.6M, EPS $(5.37) — 10-Q Summary - TradingView
NVNO Q2'26 Earnings: EPS estimate is (4.69) USD - TradingView
enVVeno Medical Corp (NVNO) Cash Flow - TradingKey
enVVeno Medical Corp expected to post a loss of $4.69 a shareEarnings Preview - TradingView
enVVeno Medical Corporation Revenue Breakdown – LS:A42085 - TradingView
enVVeno Medical Corp (NVNO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
enVVeno Medical Corp (NVNO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
enVVeno Medical Corp (NVNO) Income Statement - TradingKey
NVNO|enVVeno Medical Corp|Price:10.390|Chg%:+0.160 - TradingKey
NVNO|enVVeno Medical Corp|Price:10.320|Chg%:-0.070 - TradingKey
enVVeno Medical Corp (NVNO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NVNO Q3 2025 Earnings: Narrowing Losses Signal Cost DisciplineEarnings Expansion Phase - dars.gov.et
enVVeno Medical (NVNO) Surges 5% as Volume Spikes – Key Levels to WatchZigzag Correction - dars.gov.et
NVNO Q3 2025 Earnings: Narrower Loss Surprises as Company Advances Venous Therapy PipelineBanking Earnings Report - po-news-eg.net
enVVeno Medical (NVNO) Holds Near Support Amid Minimal Price MovementHigh Yield Stocks - Vinanet
NVNO Q3 2025 Earnings: Narrower Loss Than Expected as enVVeno Controls CostsDividend Cut Risk - Vinanet
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Signals Cost DisciplineEarnings Manipulation Risk - dars.gov.et
NVNO Q3 2025 Earnings: Narrower-than-Expected Loss Despite Stock PullbackOne-Time Gain Impact - Vinanet
EnVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor What This Means Segment - marketscreener.com
enVVeno Medical Updates Investors With New Presentation - The Globe and Mail
NVNO Q3 2025 Earnings: Smaller-Than-Expected Loss Boosts Investor SentimentManagement Tone Analysis - Vinanet
enVVeno Medical highlights newly issued U.S. patent - TipRanks
enVVeno Medical (NVNO) Secures U.S. Patent and Advances FDA Tria - GuruFocus
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment - ACCESS Newswire
enVVeno's non-surgical valve trial gets first-ever FDA IDE approval - Stock Titan
enVVeno Medical (NASDAQ: NVNO) releases updated investor presentation - Stock Titan
enVVeno Medical Corporation (NVNO) Q3 2025 Earnings: Narrower-Than-Expected Loss Bolsters Cash Runway FocusGuidance Upgrade Report - Vinanet
Price to earnings forward of enVVeno Medical Corporation – BOATS:NVNO - TradingView
NVNO Forecast — Price Target — Prediction for 2027 - TradingView
A42085 Forecast — Price Target — Prediction for 2027 - TradingView
enVVeno Medical receives U.S. patent for venous valve system By Investing.com - Investing.com Nigeria
enVVeno Medical receives U.S. patent for venous valve system - Investing.com
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial - ACCESS Newswire
enVVeno patent covers key enVVe valve parts before pivotal FDA trial - Stock Titan
enVVeno Medical (NVNO) Gains 2.6% as Shares Test Key Resistance Near $11.67Ascending Triangle - dars.gov.et
NVNO Q3 2025 Earnings: Narrowing Losses Underpin Optimism as Clinical Progress ContinuesMid-Term Outlook - dars.gov.et
NVNO Q3 2025 Earnings: Narrower-than-Expected Loss Highlights Cost DisciplineTech Earnings Analysis - dars.gov.et
Enterprise value to revenue forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Price to sales forward of enVVeno Medical Corporation – NASDAQ:NVNO - TradingView
Envveno Medical Corp (NVNO) 財務データ
収益
当期純利益
現金流量
EPS
1.36%
大文字化:
|
ボリューム (24 時間):